Adimab

Adimab is an industry leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, and translating target hypotheses into therapeutically relevant antibody drugs. Adimab has started more than 360 antibody discovery campaigns with more than 80eighty partners, which rangesrange from top academic institutions to top pharma companies.

It is a company that focuses on developing human monoclonal and bispecific antibodies for oncology, immunomodulation, inflammation, neuroscience and pain.

The company focuses on developing human monoclonal and bispecific antibodies for oncology, immunomodulation, inflammation, neuroscience and pain. The Adimab has a platform that is based on synthetic and natural immune repertoires, which are propagated and screened in its proprietary yeast system. Its technology allows selecting key antibody properties in real-timereal time.